Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer

NCT02543645 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT02543645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02543645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Lead sponsor
Celldex Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2015
Completion date
May 22, 2017
Enrollment
18 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, carcinoma, renal cell, clear-cell metastatic renal cell carcinoma, head and neck cancer, kidney diseases, kidney neoplasms, melanoma, neoplasms, neoplasms by histologic type, non-small cell lung cancer, triple negative breast cancer, urogenital neoplasms, urologic diseases, urologic neoplasms